Search

Your search keyword '"Chia, Stephen K."' showing total 270 results
Start Over Author "Chia, Stephen K."
270 results on '"Chia, Stephen K."'

1. On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).

Author

Chia, Stephen K. L., primary, Solovieff, Nadia, additional, Joshi, Mukta, additional, Im, Seock-Ah, additional, Bianchi, Giulia Valeria, additional, de la Cruz-Merino, Luis, additional, Jerusalem, Guy Heinrich Maria, additional, Sonke, Gabe S., additional, Nusch, Arnd, additional, Beck, J. Thaddeus, additional, Slamon, Dennis J., additional, Wang, Craig, additional, Zarate, Juan Pablo, additional, Su, Fei, additional, and Neven, Patrick, additional

Published
2024
Full Text
View/download PDF

2. Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.

Author

Abdou, Yara, primary, Hoag, Jess R, additional, Barlow, William E., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K. L., additional, Dhesy-Thind, Sukhbinder K., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Racz, Jennifer M., additional, Tripathy, Debashish, additional, Hortobagyi, Gabriel N., additional, Pusztai, Lajos, additional, Sharma, Priyanka, additional, and Kalinsky, Kevin, additional

Published
2024
Full Text
View/download PDF

3. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.

Author

Yardley, Denise A., primary, Untch, Michael, additional, Barrios, Carlos H., additional, Bardia, Aditya, additional, Kalinsky, Kevin, additional, Im, Seock-Ah, additional, Chia, Stephen K. L., additional, Ring, Alistair E., additional, McAndrew, Nicholas Patrick, additional, Valero, Vicente, additional, Ruiz-Borrego, Manuel, additional, Fresco, Rodrigo, additional, Sum, Eleanor, additional, Chattar, Yogesh, additional, Waters, Sorcha, additional, and Harbeck, Nadia, additional

Published
2024
Full Text
View/download PDF

4. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).

Author

Kalinsky, Kevin, primary, Barlow, William E., additional, Pathak, Harsh B, additional, Gralow, Julie R., additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K. L., additional, Rastogi, Priya, additional, Schott, Anne F., additional, Shak, Steven, additional, Tripathy, Debashish, additional, Hortobagyi, Gabriel N., additional, Meric-Bernstam, Funda, additional, Sharma, Priyanka, additional, Pusztai, Lajos, additional, Thompson, Alastair Mark, additional, and Godwin, Andrew K., additional

Published
2024
Full Text
View/download PDF

5. Supplementary Figure S1 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Author

Mamounas, Eleftherios P., primary, Bandos, Hanna, primary, Rastogi, Priya, primary, Zhang, Yi, primary, Treuner, Kai, primary, Lucas, Peter C., primary, Geyer, Charles E., primary, Fehrenbacher, Louis, primary, Chia, Stephen K., primary, Brufsky, Adam M., primary, Walshe, Janice M., primary, Soori, Gamini S., primary, Dakhil, Shaker, primary, Paik, Soonmyung, primary, Swain, Sandra M., primary, Sgroi, Dennis C., primary, Schnabel, Catherine A., primary, and Wolmark, Norman, primary

Published
2024
Full Text
View/download PDF

6. Data from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Author

Mamounas, Eleftherios P., primary, Bandos, Hanna, primary, Rastogi, Priya, primary, Zhang, Yi, primary, Treuner, Kai, primary, Lucas, Peter C., primary, Geyer, Charles E., primary, Fehrenbacher, Louis, primary, Chia, Stephen K., primary, Brufsky, Adam M., primary, Walshe, Janice M., primary, Soori, Gamini S., primary, Dakhil, Shaker, primary, Paik, Soonmyung, primary, Swain, Sandra M., primary, Sgroi, Dennis C., primary, Schnabel, Catherine A., primary, and Wolmark, Norman, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Table from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Author

Mamounas, Eleftherios P., primary, Bandos, Hanna, primary, Rastogi, Priya, primary, Zhang, Yi, primary, Treuner, Kai, primary, Lucas, Peter C., primary, Geyer, Charles E., primary, Fehrenbacher, Louis, primary, Chia, Stephen K., primary, Brufsky, Adam M., primary, Walshe, Janice M., primary, Soori, Gamini S., primary, Dakhil, Shaker, primary, Paik, Soonmyung, primary, Swain, Sandra M., primary, Sgroi, Dennis C., primary, Schnabel, Catherine A., primary, and Wolmark, Norman, primary

Published
2024
Full Text
View/download PDF

12. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

Author

DeMichele, Angela, Yee, Douglas, Berry, Donald A, Albain, Kathy S, Benz, Christopher C, Boughey, Judy, Buxton, Meredith, Chia, Stephen K, Chien, Amy J, Chui, Stephen Y, Clark, Amy, Edmiston, Kirsten, Elias, Anthony D, Forero-Torres, Andres, Haddad, Tufia C, Haley, Barbara, Haluska, Paul, Hylton, Nola M, Isaacs, Claudine, Kaplan, Henry, Korde, Larissa, Leyland-Jones, Brian, Liu, Minetta C, Melisko, Michelle, Minton, Susan E, Moulder, Stacy L, Nanda, Rita, Olopade, Olufunmilayo I, Paoloni, Melissa, Park, John W, Parker, Barbara A, Perlmutter, Jane, Petricoin, Emanuel F, Rugo, Hope, Symmans, Fraser, Tripathy, Debasish, van't Veer, Laura J, Viscusi, Rebecca K, Wallace, Anne, Wolf, Denise, Yau, Christina, and Esserman, Laura J

Subjects
Humans, Breast Neoplasms, Treatment Outcome, Chemotherapy, Adjuvant, Neoadjuvant Therapy, Female, Clinical Trials as Topic, Drug Discovery, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the many new drugs and potential synergistic combinations, the neoadjuvant approach has been used to test benefit of drug combinations in clinical trials of primary breast cancer. A recent FDA-led meta-analysis showed that pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who have specific breast cancer subtypes. This meta-analysis motivated the FDA's draft guidance for using pCR as a surrogate endpoint in accelerated drug approval. Using pCR as a registration endpoint was challenged at ASCO 2014 Annual Meeting with the presentation of ALTTO, an adjuvant trial in HER2-positive breast cancer that showed a nonsignificant reduction in DFS hazard rate for adding lapatinib, a HER-family tyrosine kinase inhibitor, to trastuzumab and chemotherapy. This conclusion seemed to be inconsistent with the results of NeoALTTO, a neoadjuvant trial that found a statistical improvement in pCR rate for the identical lapatinib-containing regimen. We address differences in the two trials that may account for discordant conclusions. However, we use the FDA meta-analysis to show that there is no discordance at all between the observed pCR difference in NeoALTTO and the observed HR in ALTTO. This underscores the importance of appropriately modeling the two endpoints when designing clinical trials. The I-SPY 2/3 neoadjuvant trials exemplify this approach.

Published
2015

14. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

Author

Mamounas, Eleftherios P, primary, Bandos, Hanna, additional, Rastogi, Priya, additional, Lembersky, Barry C, additional, Jeong, Jong-Hyeon, additional, Geyer, Charles E, additional, Fehrenbacher, Louis, additional, Chia, Stephen K, additional, Brufsky, Adam M, additional, Walshe, Janice M, additional, Soori, Gamini S, additional, Dakhil, Shaker R, additional, Wade, James L, additional, McCarron, Edward C, additional, Swain, Sandra M, additional, and Wolmark, Norman, additional

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 4 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, primary, Kilburn, Lucy, primary, Fribbens, Charlotte, primary, Beaney, Matthew, primary, Garcia-Murillas, Isaac, primary, Budzar, Aman U., primary, Robertson, John F.R., primary, Gradishar, William, primary, Piccart, Martine, primary, Schiavon, Gaia, primary, Bliss, Judith M., primary, Dowsett, Mitch, primary, Johnston, Stephen R.D., primary, and Chia, Stephen K., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 6 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, primary, Kilburn, Lucy, primary, Fribbens, Charlotte, primary, Beaney, Matthew, primary, Garcia-Murillas, Isaac, primary, Budzar, Aman U., primary, Robertson, John F.R., primary, Gradishar, William, primary, Piccart, Martine, primary, Schiavon, Gaia, primary, Bliss, Judith M., primary, Dowsett, Mitch, primary, Johnston, Stephen R.D., primary, and Chia, Stephen K., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 3 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, primary, Kilburn, Lucy, primary, Fribbens, Charlotte, primary, Beaney, Matthew, primary, Garcia-Murillas, Isaac, primary, Budzar, Aman U., primary, Robertson, John F.R., primary, Gradishar, William, primary, Piccart, Martine, primary, Schiavon, Gaia, primary, Bliss, Judith M., primary, Dowsett, Mitch, primary, Johnston, Stephen R.D., primary, and Chia, Stephen K., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, primary, Kilburn, Lucy, primary, Fribbens, Charlotte, primary, Beaney, Matthew, primary, Garcia-Murillas, Isaac, primary, Budzar, Aman U., primary, Robertson, John F.R., primary, Gradishar, William, primary, Piccart, Martine, primary, Schiavon, Gaia, primary, Bliss, Judith M., primary, Dowsett, Mitch, primary, Johnston, Stephen R.D., primary, and Chia, Stephen K., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Tables 1-2 from A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

Author

Chia, Stephen K., primary, Bramwell, Vivien H., primary, Tu, Dongsheng, primary, Shepherd, Lois E., primary, Jiang, Shan, primary, Vickery, Tammi, primary, Mardis, Elaine, primary, Leung, Samuel, primary, Ung, Karen, primary, Pritchard, Kathleen I., primary, Parker, Joel S., primary, Bernard, Philip S., primary, Perou, Charles M., primary, Ellis, Matthew J., primary, and Nielsen, Torsten O., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 5 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, primary, Kilburn, Lucy, primary, Fribbens, Charlotte, primary, Beaney, Matthew, primary, Garcia-Murillas, Isaac, primary, Budzar, Aman U., primary, Robertson, John F.R., primary, Gradishar, William, primary, Piccart, Martine, primary, Schiavon, Gaia, primary, Bliss, Judith M., primary, Dowsett, Mitch, primary, Johnston, Stephen R.D., primary, and Chia, Stephen K., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Data from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, primary, Kilburn, Lucy, primary, Fribbens, Charlotte, primary, Beaney, Matthew, primary, Garcia-Murillas, Isaac, primary, Budzar, Aman U., primary, Robertson, John F.R., primary, Gradishar, William, primary, Piccart, Martine, primary, Schiavon, Gaia, primary, Bliss, Judith M., primary, Dowsett, Mitch, primary, Johnston, Stephen R.D., primary, and Chia, Stephen K., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 2 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, primary, Kilburn, Lucy, primary, Fribbens, Charlotte, primary, Beaney, Matthew, primary, Garcia-Murillas, Isaac, primary, Budzar, Aman U., primary, Robertson, John F.R., primary, Gradishar, William, primary, Piccart, Martine, primary, Schiavon, Gaia, primary, Bliss, Judith M., primary, Dowsett, Mitch, primary, Johnston, Stephen R.D., primary, and Chia, Stephen K., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 1-2 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Author

Cheang, Maggie C.U., primary, Voduc, K. David, primary, Tu, Dongsheng, primary, Jiang, Shan, primary, Leung, Samuel, primary, Chia, Stephen K., primary, Shepherd, Lois E., primary, Levine, Mark N., primary, Pritchard, Kathleen I., primary, Davies, Sherri, primary, Stijleman, Inge J., primary, Davis, Carole, primary, Ebbert, Mark T.W., primary, Parker, Joel S., primary, Ellis, Matthew J., primary, Bernard, Philip S., primary, Perou, Charles M., primary, and Nielsen, Torsten O., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures 1-2 from A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

Author

Chia, Stephen K., primary, Bramwell, Vivien H., primary, Tu, Dongsheng, primary, Shepherd, Lois E., primary, Jiang, Shan, primary, Vickery, Tammi, primary, Mardis, Elaine, primary, Leung, Samuel, primary, Ung, Karen, primary, Pritchard, Kathleen I., primary, Parker, Joel S., primary, Bernard, Philip S., primary, Perou, Charles M., primary, Ellis, Matthew J., primary, and Nielsen, Torsten O., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Author

Cheang, Maggie C.U., primary, Voduc, K. David, primary, Tu, Dongsheng, primary, Jiang, Shan, primary, Leung, Samuel, primary, Chia, Stephen K., primary, Shepherd, Lois E., primary, Levine, Mark N., primary, Pritchard, Kathleen I., primary, Davies, Sherri, primary, Stijleman, Inge J., primary, Davis, Carole, primary, Ebbert, Mark T.W., primary, Parker, Joel S., primary, Ellis, Matthew J., primary, Bernard, Philip S., primary, Perou, Charles M., primary, and Nielsen, Torsten O., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure Legends 1-2 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Author

Cheang, Maggie C.U., primary, Voduc, K. David, primary, Tu, Dongsheng, primary, Jiang, Shan, primary, Leung, Samuel, primary, Chia, Stephen K., primary, Shepherd, Lois E., primary, Levine, Mark N., primary, Pritchard, Kathleen I., primary, Davies, Sherri, primary, Stijleman, Inge J., primary, Davis, Carole, primary, Ebbert, Mark T.W., primary, Parker, Joel S., primary, Ellis, Matthew J., primary, Bernard, Philip S., primary, Perou, Charles M., primary, and Nielsen, Torsten O., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 1 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Author

Cheang, Maggie C.U., primary, Voduc, K. David, primary, Tu, Dongsheng, primary, Jiang, Shan, primary, Leung, Samuel, primary, Chia, Stephen K., primary, Shepherd, Lois E., primary, Levine, Mark N., primary, Pritchard, Kathleen I., primary, Davies, Sherri, primary, Stijleman, Inge J., primary, Davis, Carole, primary, Ebbert, Mark T.W., primary, Parker, Joel S., primary, Ellis, Matthew J., primary, Bernard, Philip S., primary, Perou, Charles M., primary, and Nielsen, Torsten O., primary

Published
2023
Full Text
View/download PDF

28. Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007)

Author

Abdou, Yara, primary, Barlow, William E., additional, Gralow, Julie R., additional, Meric-Bernstam, Funda, additional, Albain, Kathy S., additional, Hayes, Daniel F., additional, Lin, Nancy U., additional, Perez, Edith A., additional, Goldstein, Lori J., additional, Chia, Stephen K., additional, Dhesy-Thind, Sukhbinder, additional, Rastogi, Priya, additional, Alba, Emilio, additional, Delaloge, Suzette, additional, Schott, Anne F., additional, Shak, Steven, additional, Sharma, Priyanka, additional, Lew, Danika L., additional, Miao, Jieling, additional, Unger, Joseph M., additional, Tripathy, Debu, additional, Pusztai, Lajos, additional, Hortobagyi, Gabriel N., additional, and Kalinsky, Kevin, additional

Published
2023
Full Text
View/download PDF

29. Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)

Author

Geyer, Jr, Charles E., primary, Tang, Gong, additional, Rastogi, Priya, additional, Valero, Vicente, additional, Chia, Stephen K., additional, Cobain, Erin F., additional, Obeid, Elias, additional, Page, David B., additional, Poklepovic, Andrew S., additional, Irvin, Jr., William J., additional, Brufsky, Adam M., additional, Wapnir, Irene L., additional, Suga, Jennifer M., additional, Mamounas, Eleftherios (Terry), additional, and Wolmark, Norman, additional

Published
2023
Full Text
View/download PDF

30. Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

Author

Andre, Fabrice, primary, Solovieff, Nadia, additional, Su, Faye, additional, Bardia, Aditya, additional, Neven, Patrick, additional, Yap, Yoon-Sim, additional, Tripathy, Debu, additional, Lu, Yen-Shen, additional, Slamon, Dennis, additional, Chia, Stephen K., additional, Joshi, Mukta, additional, Chakravartty, Arunava, additional, Lteif, Agnes, additional, Taran, Tetiana, additional, and Arteaga, Carlos, additional

Published
2023
Full Text
View/download PDF

31. Abstract PD13-06: PD13-06 Long-Term and Very-Long-Term Disease Control in Patients From BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer

Author

Rugo, Hope, primary, Chia, Stephen K., additional, Cortés, Javier, additional, Curigliano, Giuseppe, additional, Neven, Patrick, additional, Dent, Rebecca, additional, Tolaney, Sara, additional, Ciruelos, Eva, additional, Park, Yeon H., additional, Roux, Estelle, additional, Chattar, Yogesh, additional, Patino, Heather, additional, Akdere, Murat, additional, and Juric, Dejan, additional

Published
2023
Full Text
View/download PDF

32. Abstract OT3-26-01: CCTG MA40: DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FULVESTRANT AND IPATASERTIB FOR ADVANCED HER-2 NEGATIVE AND ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCER POST FIRST LINE CDK 4/6 AND AROMATASE INHIBITOR THERAPY (FINER)

Author

Chia, Stephen K., primary, Cescon, David W., additional, Redfern, Andrew D., additional, Rodin, Danielle, additional, Simmons, Christine, additional, Ayoub, Jean-Pierre, additional, Chalchal, Haji Ibrahim, additional, Rayson, Daniel, additional, Rushton-Marovac, Moira, additional, Hay, Tracey, additional, Gallinaro, Lisa, additional, Chen, Bingshu, additional, and Parulekar, Wendy, additional

Published
2023
Full Text
View/download PDF

33. Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B

Author

Juric, Dejan, primary, Turner, Nicholas, additional, Loi, Sherene, additional, Andre, Fabrice, additional, Chia, Stephen K., additional, Jhaveri, Komal, additional, Neven, Patrick, additional, Dent, Rebecca, additional, Ciruelos, Eva, additional, Joshi, Mukta, additional, Roux, Estelle, additional, Patino, Heather, additional, Akdere, Murat, additional, and Rugo, Hope, additional

Published
2023
Full Text
View/download PDF

34. Abstract P1-02-01: Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis

Author

Janni, Wolfgang, primary, Untch, Michael, additional, Harbeck, Nadia, additional, Gilgorov, Joseph, additional, Jacot, William, additional, Chia, Stephen K., additional, Boileau, Jean-Francois, additional, Haftchenary, Sina, additional, Gupta, Rhea, additional, Mishra, Namita, additional, Pathak, Purnima, additional, and Curigliano, Giuseppe, additional

Published
2023
Full Text
View/download PDF

35. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Chan, Arlene, Delaloge, Suzette, Holmes, Frankie A, Moy, Beverly, Iwata, Hiroji, Harvey, Vernon J, Robert, Nicholas J, Silovski, Tajana, Gokmen, Erhan, von Minckwitz, Gunter, Ejlertsen, Bent, Chia, Stephen K L, Mansi, Janine, Barrios, Carlos H, Gnant, Michael, Buyse, Marc, Gore, Ira, Smith, John, II, Harker, Graydon, Masuda, Norikazu, Petrakova, Katarina, Zotano, Angel Guerrero, Iannotti, Nicholas, Rodriguez, Gladys, Tassone, Pierfrancesco, Wong, Alvin, Bryce, Richard, Ye, Yining, Yao, Bin, and Martin, Miguel

Published
2016
Full Text
View/download PDF

36. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Author

Chia, Stephen K. L., Martin, Miguel, Holmes, Frankie A., Ejlertsen, Bent, Delaloge, Suzette, Moy, Beverly, Iwata, Hiroji, von Minckwitz, Gunter, Mansi, Janine, Barrios, Carlos H., Gnant, Michael, Tomašević, Zorica, Denduluri, Neelima, Šeparović, Robert, Kim, Sung-Bae, Jakobsen, Erik Hugger, Harvey, Vernon, Robert, Nicholas, Smith, II, John, Harker, Graydon, Zhang, Bo, Eli, Lisa D., Ye, Yining, Lalani, Alshad S., Buyse, Marc, and Chan, Arlene

Published
2019
Full Text
View/download PDF

41. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Author

Clemons, Mark J., Cochrane, Brandy, Pond, Gregory R., Califaretti, Nadia, Chia, Stephen K. L., Dent, Rebecca Alexandra, Song, Xinni, Robidoux, Andre, Parpia, Sameer, Warr, David, Rayson, Daniel, Pritchard, Kathleen I., and Levine, Mark N.

Published
2014
Full Text
View/download PDF

42. Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Author

Rastogi, Priya, primary, Bandos, Hanna, additional, Lucas, Peter C., additional, van 't Veer, Laura, additional, Wei, Jia-Perng Jennifer, additional, Geyer, Charles E., additional, Fehrenbacher, Louis, additional, Graham, Mark, additional, Chia, Stephen K. L., additional, Brufsky, Adam, additional, Walshe, Janice Maria, additional, Soori, Gamini S., additional, Dakhil, Shaker R., additional, Paik, Soonmyung, additional, Swain, Sandra M., additional, Menicucci, Andrea, additional, Wang, Shiyu, additional, Audeh, M. William, additional, Wolmark, Norman, additional, and Mamounas, Eleftherios P., additional

Published
2021
Full Text
View/download PDF

43. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

Author

Slamon, Dennis J., primary, Neven, Patrick, additional, Chia, Stephen K. L., additional, Jerusalem, Guy Heinrich Maria, additional, De Laurentiis, Michelino, additional, Im, Seock-Ah, additional, Petrakova, Katarina, additional, Bianchi, Giulia Valeria, additional, Martin, Miguel, additional, Nusch, Arnd, additional, Sonke, Gabe S., additional, de la Cruz-Merino, Luis, additional, Beck, J. Thaddeus, additional, Wang, Craig, additional, Deore, Uday, additional, Chakravartty, Arunava, additional, Zarate, Juan Pablo, additional, Taran, Tetiana, additional, and Fasching, Peter A., additional

Published
2021
Full Text
View/download PDF

44. Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.

Author

Chia, Stephen K. L., primary, Ruiz-Borrego, Manuel, additional, Drullinsky, Pamela, additional, Juric, Dejan, additional, Bachelot, Thomas, additional, Rugo, Hope S., additional, Ciruelos, Eva M., additional, Lerebours, Florence, additional, Prat, Aleix, additional, Akdere, Murat, additional, Arce, Christina, additional, Gu, Ennan, additional, and Turner, Nicholas C., additional

Published
2021
Full Text
View/download PDF

45. Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Author

Mamounas, Eleftherios P., primary, Bandos, Hanna, additional, Rastogi, Priya, additional, Zhang, Yi, additional, Treuner, Kai, additional, Lucas, Peter C., additional, Geyer, Charles E., additional, Fehrenbacher, Louis, additional, Graham, Mark, additional, Chia, Stephen K. L., additional, Brufsky, Adam, additional, Walshe, Janice Maria, additional, Soori, Gamini S., additional, Dakhil, Shaker R., additional, Paik, Soonmyung, additional, Swain, Sandra M., additional, Sgroi, Dennis, additional, Schnabel, Catherine A., additional, and Wolmark, Norman, additional

Published
2021
Full Text
View/download PDF

49. ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Author

Turner, Nicholas C., primary, Swift, Claire, additional, Kilburn, Lucy, additional, Fribbens, Charlotte, additional, Beaney, Matthew, additional, Garcia-Murillas, Isaac, additional, Budzar, Aman U., additional, Robertson, John F.R., additional, Gradishar, William, additional, Piccart, Martine, additional, Schiavon, Gaia, additional, Bliss, Judith M., additional, Dowsett, Mitch, additional, Johnston, Stephen R.D., additional, and Chia, Stephen K., additional

Published
2020
Full Text
View/download PDF

50. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.

Author

Rugo, Hope S., primary, Lerebours, Florence, additional, Ciruelos, Eva, additional, Drullinsky, Pamela, additional, Ruiz Borrego, Manuel, additional, Neven, Patrick, additional, Park, Yeon Hee, additional, Prat, Aleix, additional, Bachelot, Thomas, additional, Juric, Dejan, additional, Turner, Nicholas C., additional, Sophos, Nickolas, additional, Zarate, Juan Pablo, additional, Arce, Christina, additional, Shen, Yu-Ming, additional, and Chia, Stephen K. L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results